Women at high risk for breast cancer and OVCA, having a mutation in either BRCA1 or BRCA2 genes, may prophylactically take selective estrogen receptor modulators (SERMs), such as 4-hydroxytamoxifen (4OHT), to decrease their risk of developing breast cancer [31]. This evidence concerns the gene ESR1 and breast carcinoma.